2-异丁基-2-甲基-1,3-丙烷二醇 | 25462-42-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-异丁基-2-甲基-1,3-丙烷二醇
• 英文名称: 2-Isobutyl-2-methyl-propan-1,3-diol
• 英文别名: 2,4-Dimethyl-2-hydroxymethyl-pentanol-(1)；2-isobutyl-2-methyl-propane-1,3-diol；1,3-Propanediol, 2-isobutyl-2-methyl-；2-methyl-2-(2-methylpropyl)propane-1,3-diol
• CAS: 25462-42-4
• 化学式: C₈H₁₈O₂
• 分子量: 146.23
• InChiKey: REQVMPVOKUHDOZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2905399090

文献信息

• Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use
  申请人：deLong A. Mitchell

  公开号：US20070254920A1

  公开（公告）日：2007-11-01

  This invention relates to novel homotopic prodrugs and medicaments and methods for their preparation, testing and use. In one embodiment, the homotopic prodrug has the general formula wherein is a biologically-active moiety comprising a carboxylic acid functional group, and R b is a homotopically-symmetrical alcohol bonded to the biologically-active moiety through the carboxylic acid functional group to form an ester linkage, as well as optical isomers, enantiomers, pharmaceutically acceptable salts, biohydrolyzable amides, esters, and imides thereof and combinations thereof.

  这项发明涉及新型同位素前药、药物以及其制备、测试和使用方法。在一个实施例中，同位素前药具有一般公式 其中 是包含羧酸官能团的生物活性基团，而 R b 是通过羧酸官能团与生物活性基团形成酯键的同位对称醇，以及其光学异构体、对映异构体、药用可接受盐、生物水解酰胺、酯、亚酰胺及其组合物。
• AMINOTHIAZOLE DERIVATIVE
  申请人：Yabuuchi Tetsuya

  公开号：US20120220767A1

  公开（公告）日：2012-08-30

  A compound represented by formula (1) or a pharmaceutically acceptable salt thereof, which has a PI3 kinase γ inhibitory effect and is useful as a prophylactic or therapeutic agent for articular rheumatism, Crohn's disease, irritable colitis, Sjoegren's syndrome, multiple sclerosis, systemic lupus erythematosus, asthma, atopic dermatitis, arteriosclerosis, organ transplant rejection, cancer, retinopathy, psoriasis, arthrosis deformans, age-related macular degeneration, type II diabetes, insulin resistance, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), hyperlipemia, etc.

  由式（1）表示的化合物或其药学上可接受的盐，具有PI3激酶γ抑制作用，可用作关节风湿、克罗恩病、肠易激综合征、干燥综合征、多发性硬化、系统性红斑狼疮、哮喘、特应性皮炎、动脉硬化、器官移植排斥、癌症、视网膜病变、牛皮癣、关节病变、年龄相关性黄斑变性、2型糖尿病、胰岛素抵抗、肥胖、非酒精性脂肪肝病（NAFLD）、非酒精性脂肪性肝炎（NASH）、高脂血症等疾病的预防或治疗剂。
• Concentrated, stable, preferably clear, fabric softening composition
  申请人：Trinh Toan

  公开号：US20060058216A1

  公开（公告）日：2006-03-16

  Principal solvents, especially mono-ol and diol principal solvents, having a ClogP of from about 0.15 to about 0.64, preferably from about 0.25 to about 0.62, and more preferably from about 0.40 to about 0.60, are disclosed that have the ability to make clear aqueous fabric softener compositions containing relatively high concentrations of fabric softener actives having ester linkages in their long, hydrophobic chains. The fabric softener actives are either unsaturated, or have intermediate length chains (˜C 12-14 ) and the said principal solvents are used at levels of less than about 40%. Other solvents may be present. Some of the said principal solvents are novel compounds and/or novel mixtures. Premixes of the fabric softening actives, the principal solvents, and, optionally, other solvents are useful in the preparation of complete formulations by obviating/limiting the need for heating.

  本发明揭示了主要溶剂，特别是具有ClogP约为0.15至约0.64，优选为约0.25至约0.62，更优选为约0.40至约0.60的单醇和双醇主要溶剂，具有制备含有长链疏水基中酯键的相对高浓度织物柔顺剂活性成分的清澈水性织物柔顺剂组合物的能力。织物柔顺剂活性成分可以是不饱和的，也可以具有中等长度的链（约C12-14），所述主要溶剂的使用水平小于约40％。其他溶剂可以存在。其中一些主要溶剂是新化合物和/或新混合物。织物柔顺剂活性成分、主要溶剂和可选的其他溶剂的预混物在制备完整配方时是有用的，因为它们可以避免/限制加热的需要。
• Concentrated, stable fabric softening composition
  申请人：——

  公开号：US20030153483A1

  公开（公告）日：2003-08-14

  Principal solvents, especially mono-ol and diol principal solvents, having a ClogP of from about 0.15 to about 0.64, preferably from about 0.25 to about 0.62, and more preferably from about 0.40 to about 0.60, are disclosed that have the ability to make clear aqueous fabric softener compositions containing relatively high concentrations of fabric softener actives having ester linkages in their long, hydrophobic chains. The fabric softener actives are either unsaturated, or have intermediate length chains (˜C 12-14 ) and the said principal solvents are used at levels of less than about 40%. Other solvents may be present. Some of the said principal solvents are novel compounds and/or novel mixtures. Premixes of the fabric softening actives, the principal solvents, and, optionally, other solvents are useful in the preparation of complete formulations by obviating/limiting the need for heating.

  本发明涉及主要溶剂，特别是具有从约0.15到约0.64的ClogP值的单醇和二醇主要溶剂，优选从约0.25到约0.62，更优选从约0.40到约0.60，具有使含有长的亲水性链中的酯键的织物柔软剂活性成分相对高浓度的清澈水性织物柔软剂组合物的能力。织物柔软剂活性成分可以是不饱和的，也可以具有中等长度的链（约C12-14），所述主要溶剂的使用水平低于约40％。其他溶剂可能也存在。其中一些主要溶剂是新化合物和/或新混合物。织物柔软剂活性成分、主要溶剂和可选的其他溶剂的预混物可用于制备完整配方，从而避免/限制加热的需要。
• ISOQUINOLINONE DERIVATIVES
  申请人：BROUGH Stephen John

  公开号：US20100099665A1

  公开（公告）日：2010-04-22

  The present invention relates to isoquinolinone derivatives of formula (I): wherein are as herein defined; processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明涉及式(I)的异喹啉酮衍生物，其中定义如下；制备它们的方法，含有它们的制药组合物以及它们在治疗中的应用。